For research use only. Not for therapeutic Use.
BDM-2 is an IN-LEDGF allosteric inhibitor (INLAI) of HIV-1 integrase (IN refers to integrase) (IC50=47 nM) with potent anti-Retroviral (ARV) activity. BDM-2 shows IN multimerization activation effect with an AC50 value of 20 nM. BDM-2 blocks the interaction between the catalytic core domain of IN (IN-CCD) and the Integrase binding domain of LEDGF/p75 (IBD), with an IC50 value of 0.15 μM. BDM-2 exhibits highly selective and favorable cytotoxicity[1].
| Catalog Number | I041703 |
| CAS Number | 1643876-33-8 |
| Synonyms | (2S)-2-[3-cyclopropyl-2-(3,4-dihydro-2H-chromen-6-yl)-6-methylphenyl]-2-[(2-methylpropan-2-yl)oxy]acetic acid |
| Molecular Formula | C25H30O4 |
| Purity | ≥95% |
| InChI | InChI=1S/C25H30O4/c1-15-7-11-19(16-8-9-16)22(21(15)23(24(26)27)29-25(2,3)4)18-10-12-20-17(14-18)6-5-13-28-20/h7,10-12,14,16,23H,5-6,8-9,13H2,1-4H3,(H,26,27)/t23-/m0/s1 |
| InChIKey | UDFCYQOJPMKLMT-QHCPKHFHSA-N |
| SMILES | CC1=C(C(=C(C=C1)C2CC2)C3=CC4=C(C=C3)OCCC4)C(C(=O)O)OC(C)(C)C |
| Reference | [1]. Le Rouzic E, et al. Biological and structural analysis of new potent Integrase-LEDGF allosteric HIV-1 inhibitors. bioRxiv, 2023: 2023.01. 28.523533. |
